These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28678537)

  • 41. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
    O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
    Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
    Miura H; Shirai H
    Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
    [No Abstract]   [Full Text] [Related]  

  • 43. Pazopanib in the treatment of soft tissue sarcoma.
    Schöffski P
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pazopanib: Clinical development of a potent anti-angiogenic drug.
    Schutz FA; Choueiri TK; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
    Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
    Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Promising management of pazopanib-induced liver toxicity.
    Vlenterie M; van Erp NP; van der Graaf WT
    Acta Oncol; 2015 Jul; 54(7):1064-6. PubMed ID: 25734660
    [No Abstract]   [Full Text] [Related]  

  • 48. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
    Nishida Y; Urakawa H; Nakayama R; Kobayashi E; Ozaki T; Ae K; Matsumoto Y; Tsuchiya H; Goto T; Hiraga H; Naka N; Takahashi S; Ando Y; Ando M; Kuwatsuka Y; Hamada S; Ueda T; Kawai A
    Int J Cancer; 2021 Jan; 148(1):140-149. PubMed ID: 32638374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical evaluation of pazopanib eye drops in healthy subjects and in subjects with neovascular age-related macular degeneration.
    Singh R; Wurzelmann JI; Ye L; Henderson L; Hossain M; Trivedi T; Kelly DS
    Retina; 2014 Sep; 34(9):1787-95. PubMed ID: 24896137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
    Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
    Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GAS agents limit pazopanib activity in soft-tissue sarcoma.
    Gourd E
    Lancet Oncol; 2019 Mar; 20(3):e140. PubMed ID: 30799260
    [No Abstract]   [Full Text] [Related]  

  • 53. The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study).
    Lubberman FJE; Gelderblom H; Hamberg P; Vervenne WL; Mulder SF; Jansman FGA; Colbers A; van der Graaf WTA; Burger DM; Luelmo S; Moes DJAR; van Herpen CML; van Erp NP
    Clin Pharmacol Ther; 2019 Nov; 106(5):1076-1082. PubMed ID: 31125423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
    Altorki N; Lane ME; Bauer T; Lee PC; Guarino MJ; Pass H; Felip E; Peylan-Ramu N; Gurpide A; Grannis FW; Mitchell JD; Tachdjian S; Swann RS; Huff A; Roychowdhury DF; Reeves A; Ottesen LH; Yankelevitz DF
    J Clin Oncol; 2010 Jul; 28(19):3131-7. PubMed ID: 20516450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pazopanib for the treatment of breast cancer.
    Amiri-Kordestani L; Tan AR; Swain SM
    Expert Opin Investig Drugs; 2012 Feb; 21(2):217-25. PubMed ID: 22233389
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib.
    Ellawatty WEA; Masuo Y; Fujita KI; Yamazaki E; Ishida H; Arakawa H; Nakamichi N; Abdelwahed R; Sasaki Y; Kato Y
    Drug Metab Dispos; 2018 Jan; 46(1):33-40. PubMed ID: 29089306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
    Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
    Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pazopanib: retinal detachment.
    Prescrire Int; 2015 Jan; 24(156):20. PubMed ID: 25729830
    [No Abstract]   [Full Text] [Related]  

  • 60. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
    Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
    Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.